奥星生命科技(06118)发布中期业绩 股东应占溢利2499.9万元 同比增加325.37%

Core Viewpoint - Aoxing Life Science Technology (06118) reported a decrease in revenue for the six months ending June 30, 2025, while showing a significant increase in net profit attributable to shareholders [1] Financial Performance - Revenue for the period was 662 million RMB, representing a year-on-year decrease of 5.57% [1] - Net profit attributable to shareholders was 24.999 million RMB, which is a substantial increase of 325.37% compared to the previous year [1] - Basic earnings per share were reported at 0.05 RMB [1]